Guideline Atlas

Nephrotic syndrome

Also known as: FSGS · membranous nephropathy · minimal change disease

Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.

United StatesNKF/AUA
CurrentGlobal guideline

KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children

KDIGO · 2025

This guideline addresses steroid-sensitive and steroid-resistant nephrotic syndrome in children, including when to biopsy, when to pursue genetic testing, and how to sequence glucocorticoids and steroid-sparing agents. KDIGO presents it as replacing Chapter 4 of the 2021 Glomerular Diseases guideline.

  • KDIGO states this guideline updates Chapter 4 of the 2021 Glomerular Diseases guideline and was published online in April 2025. source
  • Per KDIGO, the update supports shorter initial glucocorticoid courses and drops the former first-line versus alternative distinction among steroid-sparing agents. source
EuropeERA/EAU (global: KDIGO)
CurrentGlobal guideline

KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children

KDIGO · 2025

This guideline addresses steroid-sensitive and steroid-resistant nephrotic syndrome in children, including when to biopsy, when to pursue genetic testing, and how to sequence glucocorticoids and steroid-sparing agents. KDIGO presents it as replacing Chapter 4 of the 2021 Glomerular Diseases guideline.

  • KDIGO states this guideline updates Chapter 4 of the 2021 Glomerular Diseases guideline and was published online in April 2025. source
  • Per KDIGO, the update supports shorter initial glucocorticoid courses and drops the former first-line versus alternative distinction among steroid-sparing agents. source

US vs EU key differences

No curated US/EU comparison yet for this disease.

What changed recently

  1. GLOBAL2021 (Chapter 4 of the KDIGO Glomerular Diseases guideline)20252025-04-01

    This guideline replaces Chapter 4 of the 2021 KDIGO glomerular diseases guideline, with most changes affecting treatment. It tightened the definition of infrequently relapsing disease from fewer than four to fewer than three relapses in a 12-month period and aligned its clinical definitions with the International Pediatric Nephrology Association guideline.

    source ↗curation confidence 90%

See the full update feed for changes across every system.